Nuevas metas terapéuticas en el tratamiento de las dislipemias: colesterol no HDL y remanentes de colesterol
Open Access
- 26 March 2024
- journal article
- Published by Federacion Argentina de Cardiología in Revista de la Federación Argentina de Cardiología
- Vol. 53 (1) , 5-8
Abstract
Non-HDL-C is a powerful indicator of lipoproteins rich in ApoB. Its measurement is much simpler, it does not require fasting to quantify it, not being influenced by triglyceride levels, and it is an excellent marker of atherogenic cholesterol, with a better correlation with cardiovascular risk than LDL-C. In patients in high risk of atherogenic dyslipidemia, the strategy of consideringnon-HDL-C as a primary objective is allowed, because it incorporates the risk of lipid origin better than LDL-C and because it is more feasible than measuring ApoB. The therapeutic objective of non-HDL-C is to add 30 mg/dL to the calculated LDL-C target value; in the general population, optimal non-HDL-C levels of less than 130 mg/dL are maintained. In a patient considered in very high risk, the target LDL-C is less than 55 mg/dL; thus their non-HDL-C should not exceed 85 mg/dL. Non-HDL cholesterol becomes an excellent indicator of total atherogenic cholesterol. And it is a primary therapeutic objective in individuals with atherogenic dyslipidemia. Evidence available to date shows the benefit of adding ethyl eicosapentaenoic acid to patients with elevatednon-HDL cholesterol under optimal treatment with statins, for reducing cardiovascular risk. Fibrates may be considered in patients with extreme hypertriglyceridemia.Keywords
This publication has 6 references indexed in Scilit:
- 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in AdultsCanadian Journal of Cardiology, 2021
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trialEuropean Heart Journal, 2020
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskEuropean Heart Journal, 2019
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesCirculation, 2019
- Induction of ATF3 Gene Network by Triglyceride-Rich Lipoprotein Lipolysis Products Increases Vascular Apoptosis and InflammationArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- EICOSAPENTAENOIC ACID AND PREVENTION OF THROMBOSIS AND ATHEROSCLEROSIS?The Lancet, 1978